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OBJECTIVE — The aim of this study was to investigate the role of inﬂammatory markers as
potential predictors of cardiovascular events in subjects with and without the metabolic syndrome.
RESEARCH DESIGN AND METHODS — This was a post hoc analysis from the Diet
and Omega-3 Intervention Trial (DOIT), comprising 563 elderly men with (n  221) and
without (n  342) metabolic syndrome. Circulating inﬂammatory markers were measured.
RESULTS — During 3 years, 68 cardiovascular events were recorded. In the total popula-
tion, C-reactive protein (CRP) (P  0.001), interleukin-18 (IL-18) (P  0.008), and IL-6 (P 
0.003)wereelevatedinsubjectswithevents.Insubjectswithmetabolicsyndrome,IL-18wasthe
strongest predictor (adjusted odds ratio 2.9 [95% CI 1.1–7.8]). In subjects without metabolic
syndrome, only CRP seemed to be an independent predictor (3.3 [1.5–7.3]). There was a
signiﬁcant interaction between fasting glucose and IL-18 (P  0.008) and IL-6 (P  0.024) but
not CRP. Elevated fasting glucose (6.2 mmol/l) markedly increased the predictive power of
inﬂammatory markers (IL-18: 5.5 [1.4–21.1], IL-6: 3.5 [1.0–11.8], and CRP: 3.5 [1.0–11.9]).
For IL-18, there was a stepwise increase in event rate by quartiles of fasting glucose.
CONCLUSIONS — IL-18wasanindependentpredictorofcardiovasculareventsinsubjects
with metabolic syndrome and even more so in the presence of elevated fasting glucose. Our
ﬁndings suggest a mutually potentiating effect of hyperglycemia and inﬂammation in cardiovas-
cular risk prediction.
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T
he metabolic syndrome is a cluster
ofriskfactorsforcardiovasculardis-
ease (CVD), including insulin resis-
tance, obesity, hypertension, elevated
triglycerides, and low levels of HDL cho-
lesterol (1,2). There is increasing evi-
dence that the metabolic syndrome is
associated with a proinﬂammatory state,
and whether a measure of inﬂammation
shouldbeincludedinthedeﬁnitionofthe
syndrome is currently being discussed
(1,3). However, to be included, such a
marker should preferably enhance the
prediction of CVD, and debate on
whether this is the case is ongoing.
Cross-sectional studies have shown
added prognostic information by risk
stratiﬁcation with C-reactive protein
(CRP) in populations with diabetes and
metabolicsyndrome(4).Oneprospective
study reported that combining metabolic
syndrome and CRP enhanced the prog-
nostic information for both future CVD
and new-onset diabetes (5), whereas an-
other prospective study showed that al-
though CRP and metabolic syndrome
were independent predictors of CVD, the
combination of the two did not increase
the predictive value (6).
Interleukin-18 (IL-18) is a potent
proinﬂammatorycytokinethathasbeen
reported to be associated with multiple
components of metabolic syndrome
and to predict the development of type
2 diabetes (7,8). Furthermore, IL-18
has been shown to be associated with
the formation, progression, and vulner-
abilityofatheroscleroticplaque(9–11).
However, data regarding IL-18 in pre-
dicting coronary events have been con-
ﬂicting (10,11), and IL-18 as a potential
predictor of cardiovascular events in
populations with metabolic syndrome
remains to be investigated. The aim of
the present study was to investigate in-
ﬂammatory markers as potential pre-
dictors of cardiovascular events in a
population of elderly men with or with-
out metabolic syndrome.
RESEARCH DESIGN AND
METHODS— The basis for recruit-
ment into the present study was a fol-
low-up of the participants from the Oslo
Diet and Anti-smoking Study carried out
in 1972–1977, comprising 1,232 men
with a high risk of CVD (12). Twenty-ﬁve
yearslaterthesurvivorsofthispopulation
were invited to participate in the Diet and
Omega-3 Intervention Trial on Athero-
sclerosis (DOIT), a 3-year intervention
trial with the aim of investigating the ef-
fect of n-3 polyunsaturated fatty acid
(PUFA) supplementation and/or dietary
intervention on markers of atherosclero-
sis.Thestudyhada22factorialdesign
and was placebo controlled for the n-3
PUFA capsules (13). Altogether, a total of
563 subjects, aged 64–76 years, were in-
cluded in the DOIT study. The study was
carried out in compliance with the Decla-
ration of Helsinki and was approved by
the regional ethics committee. All sub-
jects gave their written informed consent
to participate.
Deﬁnition of the metabolic
syndrome
To be classiﬁed as having the metabolic
syndrome, participants needed to have
three or more of the following criteria, as
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Panel III (ATP-III) (1): 1) abdominal obe-
sity (deﬁned as waist circumference
102 cm); 2) serum triglyceride level
1.7 mmol/l; 3) serum HDL cholesterol
level 1.0 mmol/l; 4) blood pressure
130/85mmHgordrugtreatmentforel-
evated blood pressure; and 5) fasting
plasmaglucoselevel5.6mmol/lordrug
treatment for elevated blood glucose.
Cardiovascular events
The cardiovascular events were a com-
posite of fatal and nonfatal CVD, deﬁned
as myocardial infarction, revasculariza-
tion procedures, aortic aneurism, periph-
eral arterial occlusive disease, and cere-
brovascular events, according to medical
records and the ofﬁcial death certiﬁcates
held by Statistics Norway.
Laboratory methods
Fasting blood samples, without intake of
any medications, were collected between
8 and 10 A.M. by standard venipuncture.
Serum was prepared by centrifugation
within1ha t2,500g for 10 min for deter-
minations of CRP, tumor necrosis fac-
tor- (TNF-), IL-6, IL-8, IL-10, IL-18,
and adiponectin. Monocyte chemoattrac-
tant protein-1 (MCP-1) and plasminogen
activator inhibitor type-1 (PAI-1) activi-
ties were determined in citrated plasma
(0.129 mmol/l in dilution 1:10) and
CD40 ligand (CD40L) in EDTA plasma,
all stored on ice and separated within 30
min by centrifugation at 4°C and 3,000g
for 20 min to obtain platelet-poor plas-
ma.Allsampleswerestoredat80°Cun-
til analysis.
CRP was determined by an enzyme-
linked immunosorbent assay (DRG In-
struments, Marburg/Lahn, Germany)
(detection limit 0.1 mg/l). The enzyme-
linked immunosorbent assay method
from Medical Biological Laboratories
(Naku-ku, Nagoya, Japan) was used for
analysis of IL-18. PAI-1 activity was de-
termined by Spectrolyse PL (Biopool,
Umeå, Sweden). TNF-, IL-6, IL-8, IL-
10, MCP-1, CD40L, and adiponectin
were all measured by enzyme immunoas-
says from R&D Systems Europe (Abing-
don, Oxon, U.K.) according to the
manufacturer’s instructions. For IL-10,
21sampleswerebelowthedetectionlimit
(0.5 pg/ml). In our laboratory the interas-
say coefﬁcients of variation were as fol-
lows: CRP 5%, TNF- 8.5%, IL-6
10.5%, IL-8 10.5%, IL-10 6.2%, IL-18
6.5%, MCP-1 9.0%, CD40L 9.5%, adi-
ponectin 9.5%, and PAI-1 activity 6.8%.
Serum lipids, insulin, and glucose
were determined by conventional enzy-
matic methods. Insulin resistance was es-
timated according to the homeostasis
model assessment score, calculated with
the following formula: (fasting insulin
[picomoles per liter]/7.2)/(22.5/fasting
glucose [millimoles per liter]) (14).
Table 1—Baseline characteristics in subjects with and without the metabolic syndrome
With metabolic
syndrome
Without metabolic
syndrome P value*
n 221 342
Age (years) 69.5 (67.2, 72.5) 70.4 (67.7, 72.7) 0.150
Previous CVD (%) 28 28 0.883
Current smokers (%) 28 38 0.022
Use of medication (%)
Statins 26 28 0.697
ACE inhibitors 22 10 0.001
Diabetes (%) 29 6 0.001
Impaired fasting glucose (%) 56 32 0.001
Treated hypertension (%) 40 24 0.001
BMI (kg/m
2) 28.4 (26.6, 30.6) 25.3 (23.5, 27.0) 0.001
Waist circumference (cm) 104 (99, 109) 95 (90, 99) 0.001
Triglycerides (mmol/l) 2.0 (1.8, 2.5) 1.3 (1.0, 1.6) 0.001
HDL cholesterol (mmol/l) 1.2 (1.0, 1.4) 1.5 (1.3, 1.7) 0.001
Cholesterol (mmol/l) 6.3 (5.5, 7.0) 6.4 (5.8, 7.0) 0.107
Systolic blood pressure
(mmHg) 152 (141, 164) 146 (133, 159) 0.001
Diastolic blood pressure
(mmHg) 85 (80, 92) 82 (74, 90) 0.001
Fasting glucose (mmol/l) 6.1 (5.7, 6.8) 5.4 (5.1, 5.8) 0.001
Homeostasis model
assessment score 5.4 (3.9, 7.3) 3.7 (2.9, 4.6) 0.001
CRP (mg/l) 3.64 (2.16, 6.53) 2.88 (1.50, 5.82) 0.013
IL-18 (pg/ml) 292 (231, 377) 265 (202, 341) 0.002
IL-6 (pg/ml) 1.61 (1.08, 2.62) 1.45 (0.92, 2.41) 0.047
IL-8 (pg/ml) 18.8 (15.0, 24.7) 17.4 (13.6, 23.0) 0.106
IL-10 (pg/ml) 1.39 (0.70, 3.64) 1.74 (0.77, 3.98) 0.194
CD40L (pg/ml) 57 (46, 74) 52 (43, 65) 0.003
TNF- (pg/ml) 1.21 (0.82, 2.05) 1.05 (0.77, 1.86) 0.025
MCP-1 (pg/ml) 441 (393, 563) 426 (355, 499) 0.001
Adiponectin (ng/ml) 6,703 (4,371, 10,870) 9,459 (6,167, 13,875) 0.001
PAI-1 activity (units/ml) 18.8 (12.1, 27.6) 11.4 (7.6, 18.2) 0.001
Data are median values (25th, 75th percentiles). *P values refer to differences between groups.
Table 2—Univariate and multivariate analyses of predictors of cardiovascular events (n  68)
Univariate OR
(95% CI) P value
Multivariate OR
(95% CI) P value
CRP 3.29 mg/l 3.7 (2.1–6.7) 0.001 3.0 (1.6–5.5) 0.001
Systolic blood pressure 148
mmHg 2.4 (1.4–4.2) 0.001 2.6 (1.4–4.5) 0.001
IL-6 1.53 pg/ml 2.1 (1.2–3.6) 0.006 1.4 (0.81–2.6) 0.213
Fasting glucose 6.2 mmol/l 2.0 (1.2–3.4) 0.012 1.8 (1.0–3.3) 0.041
IL-18 277 pg/ml 1.9 (1.1–3.3) 0.015 1.6 (0.90–2.8) 0.109
Smoking (yes/no) 1.9 (1.1–3.1) 0.018 2.4 (1.4–4.2) 0.003
Previous CVD 1.5 (0.88–2.6) 0.138
Cholesterol 6.3 mmol/l 1.4 (0.82–2.3) 0.238
Diet intervention (yes/no) 0.72 (0.43–1.2) 0.203
Totalpopulation(n563).Age,metabolicsyndrome,triglycerides,BMI,statinuse,ACEinhibitors,andn-3
PUFA intervention were excluded from the model (P  0.25). Cutoffs are as described in STATISTICS.
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Because the distribution of several bio-
chemical markers was skewed, data are
presentedasmedians(25th,75thpercen-
tiles), and nonparametric statistics were
used. For comparison of baseline charac-
teristics, the Mann-Whitney U test was
used for continuous data and the Pearson

2testwasusedforcategoricaldata.Anal-
ysesoftrendsthroughquartilesofinﬂam-
matory markers were performed with the

2 linear-by-linear association. Odds ra-
tios (ORs) were calculated for prediction
of events by inﬂammatory markers and
established cardiovascular risk factors.
Cutoffs for continuous variables were de-
ﬁned as greater than the 50 percentile,
except for glucose, which was divided at
the 75 percentile (6.2 mmol/l), as there
was a marked increase in events above
this level (supplemental Fig. A1 in an on-
line appendix, available at http://dx.doi.
org/10.2337/dc08-1710). Statistically sig-
niﬁcant ORs were adjusted for traditional
risk factors, use of medication, inﬂamma-
tory markers, and intervention principle.
Variables were entered in the multivariate
model if P  0.25 in the univariate model.
Diabetes was excluded from the model be-
cause of a high correlation with fasting glu-
cose (r  0.63). Potential interactions were
testedinamultipleregressionmodel.Asig-
niﬁcance level of 0.05 was used. The statis-
tical analyses were performed with SPSS
(version 15.0; SPSS, Chicago, IL).
RESULTS
Baseline characteristics
Baseline characteristics according to met-
abolic syndrome status are given in Table
1. As deﬁned by the ATP-III criteria, 221
Figure 1—Number of cardiovascular events by quartiles of IL-18, IL-6, and CRP in subjects with (f, n  221) and without ( , n  342) the
metabolic syndrome. P values refer to trend analysis. MetS, with metabolic syndrome; MetS, without metabolic syndrome; n.s., not signiﬁcant.
IL-18, glucose, and cardiovascular events
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syndrome at baseline assessment. Serum
levelsofseveralproinﬂammatorymarkers
were elevated among subjects with meta-
bolic syndrome.
Predictors of cardiovascular events
in the total population
A total of 68 cardiovascular events
(12.1%) were recorded during 3 years of
follow-up. Among inﬂammatory mark-
ers, CRP (P  0.001), IL-18 (P  0.008),
and IL-6 (P  0.003) were elevated in
subjects with cardiovascular events. The
other inﬂammatory markers did not dif-
fer between subjects with or without car-
diovascular events (supplemental Table
A1 of the online appendix). Unadjusted
and adjusted ORs for the total population
are given in Table 2. In multivariate anal-
yses, CRP, systolic blood pressure, fasting
glucose,andsmokinghabitsremainedin-
dependent predictors. Metabolic syn-
drome was not independently predictive
of cardiovascular events in the present
population.
Predictors of cardiovascular events
in subjects with or without
metabolic syndrome
In subjects with metabolic syndrome, 29
cardiovascular events (13.1%) occurred
during the study period. Analysis for
trend through quartiles showed a statisti-
cally signiﬁcant association with cardio-
vascular events for IL-18 (P  0.008),
IL-6 (P  0.003), and CRP (P  0.005)
(Fig. 1). Furthermore, in univariate anal-
yses, IL-18, IL-6, and CRP but not con-
ventional risk factors were signiﬁcantly
predictive of cardiovascular events. After
adjustment for relevant covariates, only
IL-18 remained a statistically signiﬁcant
predictor (Table 3).
In subjects without metabolic syn-
drome, 39 cardiovascular events (11.4%)
wererecorded.Analysisfortrendthrough
quartiles showed a statistically signiﬁcant
association with cardiovascular events for
CRP(P0.010)butnotforIL-18orIL-6
(Fig. 1). CRP but not IL-18 or IL-6 ap-
peared to be independently predictive of
cardiovascular events (Table 3).
To further explore the observed dif-
ference in cardiovascular prediction in
the presence and absence of metabolic
syndrome, we tested for interactions and
found signiﬁcant interactions between el-
evated fasting glucose and IL-18 (P 
0.008) and IL-6 (P  0.024) but not CRP
(P  0.240). There were no signiﬁcant
interactions between the inﬂammatory
markers and other covariates.
Figure 2 illustrates number of cardio-
vasculareventsbyquartilesofIL-18,IL-6,
and CRP in subjects with (n  139) and
without (n  424) elevated fasting glu-
cose (upper quartile 6.2 mmol/l). The
event rate by levels of IL-18 increased
stepwiseforeachquartileofglucoseinthe
total population (supplemental Table A2
andsupplementalFig.A2,availableinthe
online appendix). For all inﬂammatory
markers, ORs were higher in subjects
with elevated fasting glucose (IL-18: ad-
justed OR 5.5 [95% CI 1.4–21.1], IL-6:
3.5 [1.0–11.8], and CRP: 3.5 [1.0–
11.9]). Using the deﬁnition of impaired
fasting glucose (5.6–6.9 mmol/l) (1), the
same pattern of risk stratiﬁcation was ob-
served (data not shown).
CONCLUSIONS— The main ﬁnd-
inginthisstudyisthatIL-18stronglypre-
dicted cardiovascular events in subjects
withmetabolicsyndrome,andthepredic-
tion was even more pronounced in the
sole presence of elevated fasting glucose.
Indeed,therewasasigniﬁcantinteraction
between elevated glucose and IL-18, and
a stepwise increase in the predictive
power of IL-18 by quartiles of glucose,
consistent with a synergistic effect of
IL-18 and hyperglycemia in cardiovascu-
lar risk prediction.
Previous studies on IL-18 in predict-
ing coronary events have been conﬂicting
(10,11). In the Dallas Heart Study, IL-18
was associated with multiple metabolic
syndrome components but not with sub-
clinical atherosclerosis after adjustment
for traditional risk factors (15). The au-
thors suggested that the associations be-
tween IL-18 and atherosclerosis depend
on the presence of other risk factors such
as obesity and diabetes and that IL-18
may mediate some of the proatherogenic
effects of these factors (15).
A very recent publication reported
that inﬂammatory markers including
CRP, IL-6, and IL-18 added prognostic
information regarding cardiovascular
mortality in subjects with known coro-
nary artery disease and metabolic syn-
drome (16). In line with our results, only
IL-18 could be identiﬁed as an indepen-
dent predictor in multivariate analyses
(16). We found IL-18 to be even more
predictive in the presence of elevated glu-
cose, and as most subjects with metabolic
syndromehadimpairedfastingglucoseor
diabetes, it is likely that the predictive
value of IL-18 depends on hyperglycemia
in the present study.
IL-18 has been shown to predict the
development of type 2 diabetes (8). On
the other hand, experimental hyperglyce-
mia has been shown to increase concen-
trations of IL-18 (17). It has also been
reported that in the setting of acute myo-
cardial infarction, IL-18 and CRP were el-
evated in parallel with troponin I in
Table 3—Univariate and multivariate analyses of predictors of cardiovascular events in subjects with and without metabolic syndrome
With metabolic syndrome (29 events) Without metabolic syndrome (39 events)
Univariate OR
(95% CI)
Multivariate OR
(95% CI)
Univariate OR
(95% CI)
Multivariate OR
(95% CI)
n 221 342
IL-18 277 pg/ml 3.6 (1.4–9.3)* 2.9 (1.1–7.8)† 1.3 (0.66–2.6)
IL-6 1.53 pg/ml 3.5 (1.4–8.6)* 2.5 (0.97–6.6) 1.5 (0.76–3.0)
CRP 3.29 mg/l 3.6 (1.4–9.1)* 2.5 (0.89–6.9) 3.8 (1.8–8.1)* 3.3 (1.5–7.3)*
Systolic blood pressure 148 mmHg 2.0 (0.85–4.5) 2.8 (1.4–5.6)* 3.1 (1.4–6.5)*
Smoking (yes/no) 1.8 (0.83–4.1) 2.0 (1.0–3.9)† 2.5 (1.1–5.3)†
Fasting glucose 6.2 mmol/l 2.1 (0.97–4.7) 1.8 (0.75–4.5)
Previous CVD 1.3 (0.59–3.0) 1.6 (0.81–3.3)
Diet intervention (yes/no) 0.95 (0.44–2.0) 0.57 (0.28–1.1)
Cholesterol, age, triglycerides, BMI, statin use, ACE inhibitors, and n-3 PUFA intervention were excluded from the model (P  0.25 in univariate analysis). Cutoffs
are as described in STATISTICS .* P  0.01; †P  0.05.
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that inﬂammation might explain some of
the excess myocardial damage in hyper-
glycemic patients (18).
Our results expand these ﬁndings by
suggesting that hyperglycemia is not only
associated with increased levels of IL-18
but also fuels the potentially harmful ef-
fects of a given cytokine level. Our ﬁnd-
ings introduce the possibility of a
mutually potentiating effect of IL-18, and
elevated fasting glucose. IL-18 can stimu-
late both type 1 helper T (Th1) and Th2
responses, depending on its cytokine mi-
lieu (19), and acts synergistically with
IL-12 to stimulate a Th1 response with
production of interferon-	, a central fea-
ture in the atherosclerotic lesion (20). Re-
cently, expression of IL-12 in macro-
phageshasbeenshowntobeincreasedby
experimental hyperglycemia (21). Thus,
we speculate that our ﬁndings could in
part be explained by a Th1 response me-
diated by IL-18 acting in synergy with a
hyperglycemic proinﬂammatory milieu.
Another main ﬁnding in this study is
that CRP independently predicted car-
diovascular events in elderly high-risk
men, in contrast to a recent prospective
study reporting limited value of CRP in
risk stratiﬁcation of elderly men and
women (22). The discrepancy might be
due to the fact that our study cohort con-
sisted of only men and that a large pro-
portion had impaired fasting glucose.
Elevatedglucosewasanindependentpre-
dictor of events, and for all inﬂammatory
markers, the event rates were higher in
subjects with elevated glucose. Further-
Figure 2—Number of cardiovascular events by quartiles of IL-18, IL-6, and CRP in subjects with (f, n  139) and without ( , n  424) elevated
fasting glucose (6.2 mmol/l). P values refer to trend analysis. n.s., not signiﬁcant.
IL-18, glucose, and cardiovascular events
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between elevated fasting glucose and IL-6
in the cardiovascular risk prediction. In
total, our results point to a more general-
ized concept with increased susceptibili-
ty to inﬂammation in the presence of
hyperglycemia.
A few experimental studies may
point to the potential mechanisms in-
volved. In an in vitro study, it was
shownthattheproatherogeniceffectsof
CRP were potentiated by hyperglyce-
mia, by increased expression of adhe-
sion molecules and MCP-1 in endo-
thelial cells (23). From other in vitro
studies, it has been reported that pre-
exposure with hyperglycemia increases
lipopolysaccharide-induced secretion
of proinﬂammatory cytokines (24) and
induction of Toll-like receptor expres-
sion in human monocytes (25).
Our study has several limitations.
First, we acknowledge that our results
represent a post hoc analysis from an
intervention trial and should be inter-
preted with caution, although we have
tested for interactions and adjusted for
intervention principles as appropriate.
Second, the limited number of end
points may increase the risk of type II
errors, especially in subgroup analyses.
Thus, although multiple tests were per-
formed, the strong association between
IL-18 and end points is likely to be re-
liable. Furthermore, lack of power only
allows analyses of the combined end
point, although different mechanisms
might exist. Third, the study subjects
were quite heterogeneous, with a broad
spectrum of morbidity and medication.
Fourth, the subjects consisted of long-
time survivors from a high-risk popula-
tion, raising the possibility of survivor
bias. Finally, this study comprised a se-
lected group of elderly Caucasian men.
Different results may be obtained from
other demographic groups, and younger
cohorts could provide valuable informa-
tion regarding long-term outcomes.
Our study also has several strengths,
one of which is that metabolic syndrome
is well characterized according to the
ATP-III criteria, whereas other studies
have used BMI as a surrogate marker of
waistcircumference(5,16).Furthermore,
ourstudyisoneoffewprospectivestudies
to investigate the combined effect of met-
abolicsyndromeandinﬂammatorymark-
ers in cardiovascular risk prediction.
In summary, IL-18 was an indepen-
dent predictor of cardiovascular events
in subjects with metabolic syndrome
and even more in the presence of ele-
vated fasting glucose. Moreover, our
ﬁndings suggest the possibility of a mu-
tually potentiating effect of inﬂamma-
tion and hyperglycemia in cardiovascular
risk prediction. Further studies are
needed to conﬁrm and elucidate our
ﬁndings.
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